Skip to main content

Receptor Interactions of Dopamine and Serotonin Antagonists: Binding In Vitro and In Vivo and Receptor Regulation

  • Conference paper
Psychopharmacology: Current Trends

Part of the book series: Psychopharmacology Series ((PSYCHOPHARM,volume 5))

Abstract

The advent of receptor binding techniques has provided new ways of studying the mechanism of action of drugs. In vitro radioligand binding is now currently applied to investigate the specificity or multiple action of compounds. By using the same technique, the binding affinity of a drug can be measured for a variety of neurotransmitter, drug, peptide and ion channel receptor binding sites, providing the drug’s receptor binding profile (Leysen et al. 1981; Leysen 1984). However, in vitro receptor binding is only the initial step in the investigation of drug-receptor interactions. Investigations in vivo are required to allow evaluation of how and where a drug acts. In fact, the study of drug-receptor interactions comprises three main stages: (a) in vitro radioligand receptor binding; (b) in vivo receptor binding, providing information on the accessibility of the drugs to the receptors localized in various central and peripheral tissues, on the drug potency for occupying various receptors, on the duration of receptor occupation and on the relationship between the degree of receptor occupation and pharmacological effects; and (c) the study of receptor regulation: the effect of chronic drug treatment on receptor alterations compared with alterations in functional responses in vivo.

In this article, we will illustrate the three stages of investigation of receptor interactions and discuss the relevance and importance of the findings, using as examples three drugs known in psychopharmacological research: (a) the neuroleptic haloperidol, a prototype of a dopamine D2 antagonist: (b) Setoperone, a potential antipsychotic agent with very potent serotonin S2 and moderate D2 antagonistic activity (Ceulemans et al. 1985; Leysen et al. 1986); and (c) ritanserin, a potent and long-acting S2 antagonist (Leysen et al. 1985), which has revealed therapeutic activity in dysthymia and negative symptoms of schizophrenia (Reyntjens et al. 1986; Gelders et al. 1986). Particular attention will be paid to the problem of receptor regulation. We challenge the general applicability of the receptor regulation theory, which states that persistent receptor stimulation causes desensitisation and receptor downregulation, whereas chronic deprivation of receptor stimulation leads to supersensitivity and receptor upregulation. Recent research has revealed that the theory does not hold for S2 receptor alterations, which were found to downregulate following chronic receptor blockade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Blackshear MA, Friedman RL, Sanders-Bush E (1983) Acute and chronic effects of serotonin (5HT) antagonists on serotonin binding sites. Naunyn Schmiedebergs Arch Pharmacol 324: 125–129

    Article  PubMed  CAS  Google Scholar 

  • Campbell A, Baldessarini RJ, Teicher MH, Kula NS (1985) Prolonged antidopaminergic actions of single doses of butyrophenones in the rat. Psychopharmacology 87: 161–166

    Article  PubMed  CAS  Google Scholar 

  • Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens ASM, Janssen PAJ (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85: 329–339

    Article  PubMed  CAS  Google Scholar 

  • Creese I, Snyder SH (1980) Chronic neuroleptic treatment and dopamine receptor regulation. Adv Biochem Psychopharmacol 24: 89–94

    PubMed  CAS  Google Scholar 

  • Creese I, Burt DR, Snyder SH (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197: 596–598

    Article  PubMed  CAS  Google Scholar 

  • De Chaffoy de Courcelles D, Leysen JE, Roevens P, van Belle H (1986) The serotonin-S2 receptor: a receptor-transducer coupling model to explain insurmountable antagonist effects: Drug Dev Res 8: 173–178

    Article  Google Scholar 

  • Fleminger S, Rupniak NMJ, Hall MD, Jenner P, Marsden CD (1983) Changes in apomorphine- induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increase in D-l receptors. Biochem Pharmacol 32: 2921–2927

    Article  PubMed  CAS  Google Scholar 

  • Gandolfi O, Barbaccia ML, Costa E (1984) Comparison of iprindole, imipramine and mianserin action on brain serotonergic and beta adrenergic receptors. J Pharmacol Exp Ther 229: 782–786

    PubMed  CAS  Google Scholar 

  • Gandolfi O, Barbaccia ML, Costa E (1985) Different effects of serotonin antagonists on 3H-mianserin and 3H-ketanserin recognition sites. Life Sci 36: 713–721

    Article  PubMed  CAS  Google Scholar 

  • Gelders Y, Vanden Bussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol [Suppl 4] 9: 325–327

    Google Scholar 

  • Haase HJ (1978) The purely neuroleptic effects and its relation to the “neuroleptic threshold”. Acta Psychiatr Belg 78:19–36

    PubMed  CAS  Google Scholar 

  • Hall H, Ross SB, Sallemark M (1984) Effect of destruction of central noradrenergic and serotonergic nerve terminals by systemic neurotoxins on the long-term effects of antidepressants on β-adrenoceptors and 5-HT2 binding sites in the rat cerebral cortex. J Neural Transm 59: 9–23

    Article  PubMed  CAS  Google Scholar 

  • Hyttel J, Fredericson Overo K, Arnt J (1984) Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology 83: 20–27

    Article  PubMed  CAS  Google Scholar 

  • Katz B, Thesleff S (1957) A study of the “desensitization” produced by acetylcholine at the motor end plate. J Physiol (Lond) 138: 63–80

    CAS  Google Scholar 

  • Laduron PM, Janssen PFM, Leysen JE (1978) Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. Biochem Pharmacol 27: 317–321

    Article  PubMed  CAS  Google Scholar 

  • Leysen JE (1984) Receptors for neuroleptic drugs. In: Burrows GD, Werry JS (eds) Advances in human psychopharmacology 3. Jai, London, pp 315–356

    Google Scholar 

  • Leysen JE (1987) The use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AA, Blake GB, Juorio AV (eds) Drugs as tools in neurotransmitter research. Humana, Clifton (Neuromethods, neuropharmacology, vol 2) (in press)

    Google Scholar 

  • Leysen JE, Gommeren W (1984) The dissociation rate of unlabelled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method. J Recept Res 4: 817–845

    PubMed  CAS  Google Scholar 

  • Leysen JE, Gommeren W (1986) Drug-receptor dissociation time, new tool for drug research: receptor binding affinity and drug-receptor dissociation profiles of serotonin-S2, dopamine- D2, histamine-H1 antagonists, and opiates. Drug Dev Res 8: 119–131

    Article  CAS  Google Scholar 

  • Leysen JE, Janssen PAJ (1987) Specificity of ligands used in psychiatric research. In: Sen AK, Lee T (eds) Receptors and ligands in psychiatry and neurology, vol 1. Cambridge University Press, Cambridge (in press)

    Google Scholar 

  • Leysen JE, Niemegeers CJE (1985) Neuroleptics. In: Lajtha A (ed) Handbook of neurochemistry. Plenum, New York, pp 331–361

    Google Scholar 

  • Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168–171

    Article  PubMed  CAS  Google Scholar 

  • Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 28: 1015–1022

    Article  PubMed  CAS  Google Scholar 

  • Leysen JE, Van Gompel P, Verwimp M, Niemegeers CJE (1983) Role and localization of serotonin2 (S2)-receptor-binding sites: effects of neuronal lesions. In: Mandel P, DeFeudis FV (eds) CNS receptors–From molecular pharmacology to behavior. Raven, New York, pp 373–383

    Google Scholar 

  • Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin. A very potent and long-acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611

    PubMed  CAS  Google Scholar 

  • Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, Janssen PAJ (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology 88: 434–444

    Article  PubMed  CAS  Google Scholar 

  • Leysen JE, Van Gompel P, Gommeren W, Laduron PM (1987) Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 214–224 (Psychopharmacology series, vol 3 )

    Google Scholar 

  • Lipinski JF, Zubenko GS, Cohen BM, Barreira PJ (1984) Propranolol in the treatment of neuro-leptic induced akathisia. Am J Psychiatry 141: 412–415

    PubMed  Google Scholar 

  • Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215: 582–587

    PubMed  CAS  Google Scholar 

  • Reyntjens A, Gelder YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986) Thymosthenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8: 205–211

    Article  CAS  Google Scholar 

  • Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313

    PubMed  CAS  Google Scholar 

  • Seeman P, Grigoriadis D (1987) Dopamine receptors in brain and periphery. Neurochem Int 10: 1–25

    Article  PubMed  CAS  Google Scholar 

  • Snyder SH, Peroutka SJ (1982) A possible role of serotonin receptors in antidepressant drug action. Pharmacopsychiatry 15: 131–134

    Article  CAS  Google Scholar 

  • Strange PG (1987) Dopamine receptors in the brain and periphery: “state of the art”. Neurochem Int 10: 27–33

    Article  PubMed  CAS  Google Scholar 

  • Tarsy D, Baldessarini RJ (1974) Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13: 927–940

    Article  PubMed  CAS  Google Scholar 

  • Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system in the rat brain. Acta Physiol Scand [Suppl 367] 82: 69–93

    Google Scholar 

  • Van Wielink PS, Leysen JE (1983) Farmacologische keuzecriteria voor neuroleptica. Tijdschr Geneesmiddelenonderz 8: 1984–1997

    Google Scholar 

  • Vetulani J, Starwarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments. Arch Pharmacol 239:109114

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Leysen, J.E., Gommeren, W., Janssen, P.F.M., Van Gompel, P., Janssen, P.A.J. (1988). Receptor Interactions of Dopamine and Serotonin Antagonists: Binding In Vitro and In Vivo and Receptor Regulation. In: Casey, D.E., Christensen, A.V. (eds) Psychopharmacology: Current Trends. Psychopharmacology Series, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73280-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73280-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73282-9

  • Online ISBN: 978-3-642-73280-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics